Viatris to Buy Pacira BioSciences for $1.65 Billion -- Update
Dow Jones2026/10/08 12:25By Colin Kellaher Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio. Viatris on Thursday said it would pay $36.50 a share in cash for Pacira, a roughly 45% premium to Wednesday's closing price of $25.20 for the Brisbane, Calif., company. The deal is slated to close by the end of the year. Shares of Pacira were recently up 44% at $36.33 in premarket trading, while shares of Viatris edged down 0.1% to $17.47. Viatris said the addition of Pacira's Exparel and Zilretta products to its proposed meloxicam treatment for moderate-to-severe acute pain, positions the Canonsburg, Pa., company as a leader in non-opioid pain-management therapies. The U.S. Food and Drug Administration is currently reviewing Viatris' application for the approval of meloxicam, with a target action date of Dec. 27. Viatris said it plans to fund the Pacira acquisition primarily from excess cash, with the remainder from short-term borrowings, adding that it expects the deal will have minimal impact on its gross leverage ratio. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires October 08, 2026 08:25 ET (12:25 GMT)
By Colin Kellaher
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
Viatris on Thursday said it would pay $36.50 a share in cash for Pacira, a roughly 45% premium to Wednesday's closing price of $25.20 for the Brisbane, Calif., company.
The deal is slated to close by the end of the year.
Shares of Pacira were recently up 44% at $36.33 in premarket trading, while shares of Viatris edged down 0.1% to $17.47.
Viatris said the addition of Pacira's Exparel and Zilretta products to its proposed meloxicam treatment for moderate-to-severe acute pain, positions the Canonsburg, Pa., company as a leader in non-opioid pain-management therapies.
The U.S. Food and Drug Administration is currently reviewing Viatris' application for the approval of meloxicam, with a target action date of Dec. 27.
Viatris said it plans to fund the Pacira acquisition primarily from excess cash, with the remainder from short-term borrowings, adding that it expects the deal will have minimal impact on its gross leverage ratio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 08, 2026 08:25 ET (12:25 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
